490 Long term survival and incidence of brain metastasis in HER2- positive (HER2+) metastatic breast cancer patients (MBC) treated with trastuzumab (T): an institutional based review

V.Diéras; M.N.Guilhaume; M.Fall; J.Y.Pierga; P.Beuzeboc; P.Cottu; C.Simondi; M.Courbard; M.Mignot; A.Livartowski

首页> 外文期刊>European Journal of Cancer Supplements >490 Long term survival and incidence of brain metastasis in HER2- positive (HER2+) metastatic breast cancer patients (MBC) treated with trastuzumab (T): an institutional based review

【24h】

490 Long term survival and incidence of brain metastasis in HER2- positive (HER2+) metastatic breast cancer patients (MBC) treated with trastuzumab (T): an institutional based review

机译：490用曲妥珠单抗（T）治疗的HER2阳性（HER2 +）转移性乳腺癌患者（MBC）的长期生存和脑转移发生率：基于机构的评价

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2010年第3期|共2页
作者
V.Diéras; M.N.Guilhaume; M.Fall; J.Y.Pierga; P.Beuzeboc; P.Cottu; C.Simondi; M.Courbard; M.Mignot; A.Livartowski;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 490 Long term survival and incidence of brain metastasis in HER2- positive (HER2+) metastatic breast cancer patients (MBC) treated with trastuzumab (T): an institutional based review [J] . V.Diéras, M.N.Guilhaume, M.Fall, European Journal of Cancer Supplements . 2010,第3期

机译：490用曲妥珠单抗（T）治疗的HER2阳性（HER2 +）转移性乳腺癌患者（MBC）的长期生存和脑转移发生率：基于机构的评价
2. 5089 Shorter Overall Survival (OS) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T)+/- chemotherapy (CT) and overexpressing HER3 by immunohistochemistry (IHC) [J] . S.Gori, A.Sidoni, M.Colozza, European Journal of Cancer Supplements . 2009,第2期

机译：5089使用曲妥珠单抗（T）+/-化疗（CT）治疗并通过免疫组织化学（IHC）过表达HER3的HER2阳性（HER2 +）转移性乳腺癌（MBC）患者（pts）的总体生存期缩短
3. 2128 POSTER PTEN, EGFR, MAPK and Akt status by immunohistochemistry (IHC) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) ± chemotherapy (CT): correlation with clinical outcome [J] . S.Gori, V.De Angelis, A.Sidoni, European Journal of Cancer Supplements . 2007,第4期

机译：接受曲妥珠单抗（T）±化疗（CT）治疗的HER2阳性（HER2 +）转移性乳腺癌（MBC）患者（pts）的免疫组织化学（IHC）检测2128 POSTER PTEN，EGFR，MAPK和Akt状态
4. IMPROVING PREDICTION OF SURVIVAL USING CT-BASED TUMOR CHARACTERISTICS IN PATIENTS TREATED FOR METASTATIC NON-SMALL CELL LUNG CANCER [C] . WALKER H. LAND JR., ALAN LITWIN, DAN MARGOLIS, Artificial Neural Networks in Engineering Conference . 2010

机译：基于CT基肿瘤特征改善对转移性非小细胞肺癌的患者的肿瘤特征预测
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. 53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB) [O] . Nancy Lin, Rashmi Murthy, Carey Anders, 2020

机译：53. Tucatinib VS安慰剂加入到葡萄球菌和Capecitabine用于患有先前治疗的Her2 +转移性乳腺癌（MBC）的患者（MBC）（BM）（HER2CLIMB）
7. 53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB) [O] . Nancy Lin, Rashmi Murthy, Carey Anders, 2020

机译：53. Tucatinib VS安慰剂加入到葡萄球菌和Capecitabine，用于患有先前治疗的Her2 +转移性乳腺癌（MBC）的患者（MBC）（BM）（HER2CLIMB）

490 Long term survival and incidence of brain metastasis in HER2- positive (HER2+) metastatic breast cancer patients (MBC) treated with trastuzumab (T): an institutional based review

著录项

相似文献

相关主题

期刊订阅